Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Issue 11 (10th November 2014)

• Record Type: Journal Article
• Authors: Timms, John F.; Arslan‐Low, Elif; Kabir, Musarat; Worthington, Jenny; Camuzeaux, Stephane; Sinclair, John; Szaub, Joanna; Afrough, Babak; Podust, Vladimir N.; Fourkala, Evangelia‐Ourania; Cubizolles, Myriam; Kronenberg, Florian; Fung, Eric T.; Gentry‐Maharaj, Aleksandra; Menon, Usha; Jacobs, Ian; Everett, Allen; Ignjatovic, Vera
• Is Part Of: Proteomics. Volume 8:Issue 11/12(2014)
• Page Start: 982
• Page End: 993
• Publication Date: 2014-11-10
• Subjects: Proteomics -- Periodicals; 572.605
• DOI: 10.1002/prca.201400063
• Languages: English
• ISSNs: 1862-8346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="prca1584-sec-0010" sec-type="section"> <title>Purpose</title> <p>Ovarian cancer is a devastating disease and biomarkers for its early diagnosis are urgently required. Serum may be a valuable source of biomarkers that may be revealed by proteomic profiling. Herein, complementary serum protein profiling strategies were employed for discovery of biomarkers that could discriminate cases of malignant and benign ovarian cancer.</p> </sec> <sec id="prca1584-sec-0020" sec-type="section"> <title>Experimental design</title> <p>Identically collected and processed serum samples from 22 cases of invasive epithelial ovarian cancer, 45 benign ovarian neoplasms, and 64 healthy volunteers were subjected to immunodepletion and protein equalization coupled to 2D‐DIGE/MS and multidimensional fractionation coupled to SELDI‐TOF profiling with MS/MS for protein identification. Selected candidates were verified by ELISA in samples from malignant (<italic>n</italic> = 70) and benign (<italic>n</italic> = 89) cases and combined marker panels tested against serum CA125.</p> </sec> <sec id="prca1584-sec-0030" sec-type="section"> <title>Results</title> <p>Both profiling platforms were complementary in identifying biomarker candidates, four of which (A1AT, SLPI, APOA4, VDBP) significantly discriminated malignant from benign cases. However, no combination of markers was as good as CA125 for diagnostic accuracy. SLPI was further tested as an early marker using prediagnosis serum samples. While it rose in cases toward diagnosis, it did not discriminate prediagnosis cases from controls.</p> </sec> <sec id="prca1584-sec-0040" sec-type="section"> <title>Conclusions and clinical relevance</title> <p>The candidate biomarkers warrant further validation in independent sample sets.</p> </sec> </abstract>